Sarepta Therapeutics provided $15m in a series A round for the company, which is advancing University of Florida research.

US-based gene therapy startup AavantiBio launched yesterday with $107m in a series A round to commercialise University of Florida research. The round featured genetic medicine developer Sarepta Therapeutics, hedge fund sponsor Perceptive Advisors, investment manager RA Capital Management and Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital. AavantiBio will concentrate on…

The rest of this content is only accessible to Global University Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.